University of Bologna, Bologna, Italy.
GSK, Siena, Italy.
PLoS One. 2022 Sep 16;17(9):e0273322. doi: 10.1371/journal.pone.0273322. eCollection 2022.
Recombinant protein-based vaccines are a valid and safer alternative to traditional vaccines based on live-attenuated or killed pathogens. However, the immune response of subunit vaccines is generally lower compared to that elicited by traditional vaccines and usually requires the use of adjuvants. The use of self-assembling protein nanoparticles, as a platform for vaccine antigen presentation, is emerging as a promising approach to enhance the production of protective and functional antibodies. In this work we demonstrated the successful repetitive antigen display of the C-terminal β-barrel domain of factor H binding protein, derived from serogroup B Meningococcus on the surface of different self-assembling nanoparticles using genetic fusion. Six nanoparticle scaffolds were tested, including virus-like particles with different sizes, geometries, and physicochemical properties. Combining computational and structure-based rational design we were able generate antigen-fused scaffolds that closely aligned with three-dimensional structure predictions. The chimeric nanoparticles were produced as recombinant proteins in Escherichia coli and evaluated for solubility, stability, self-assembly, and antigen accessibility using a variety of biophysical methods. Several scaffolds were identified as being suitable for genetic fusion with the β-barrel from fHbp, including ferritin, a de novo designed aldolase from Thermotoga maritima, encapsulin, CP3 phage coat protein, and the Hepatitis B core antigen. In conclusion, a systematic screening of self-assembling nanoparticles has been applied for the repetitive surface display of a vaccine antigen. This work demonstrates the capacity of rational structure-based design to develop new chimeric nanoparticles and describes a strategy that can be utilized to discover new nanoparticle-based approaches in the search for vaccines against bacterial pathogens.
基于重组蛋白的疫苗是一种有效的、更安全的替代传统疫苗的方法,传统疫苗基于减毒或灭活的病原体。然而,与传统疫苗相比,亚单位疫苗的免疫反应通常较低,通常需要使用佐剂。自组装蛋白纳米颗粒作为疫苗抗原呈递平台的应用,正在成为一种增强保护性和功能性抗体产生的有前途的方法。在这项工作中,我们通过基因融合,证明了脑膜炎奈瑟菌 B 群因子 H 结合蛋白 C 末端β桶结构域在不同自组装纳米颗粒表面的成功重复抗原展示。我们测试了六种纳米颗粒支架,包括具有不同大小、形状和物理化学性质的病毒样颗粒。通过计算和基于结构的合理设计相结合,我们能够生成与三维结构预测紧密一致的抗原融合支架。嵌合纳米颗粒作为重组蛋白在大肠杆菌中产生,并使用多种生物物理方法评估其溶解度、稳定性、自组装和抗原可及性。已经确定了几种适合与 fHbp 的β桶进行基因融合的支架,包括铁蛋白、来自海洋栖热菌的从头设计的醛缩酶、 encapsulin、CP3 噬菌体外壳蛋白和乙型肝炎核心抗原。总之,已经对自组装纳米颗粒进行了系统筛选,以实现疫苗抗原的重复表面展示。这项工作证明了基于合理结构设计的能力,能够开发新的嵌合纳米颗粒,并描述了一种可以用于发现针对细菌病原体的新型基于纳米颗粒的方法的策略。